45 research outputs found
Celecoxib up regulates the expression of drug efflux transporter ABCG2 in breast cancer cell lines
Elevated expression of the drug efflux transporter ABCG2 seems to correlate with multidrug resistance of cancer cells. Specific COX-2 inhibitor celecoxib has been shown to enhance the sensitivity of cancer cells to anticancer drugs. To clarify whether ABCG2 inhibition is involved in the sensitizing effect of celecoxib, we investigated whether the expression of ABCG2 in breast cancer cell lines, could be modulated by celecoxib. The expression of the multidrug resistant gene (ABCG2) at mRNA and protein level was detected by real-time quantitative reverse transcription-polymerase chain reaction and flow cytometry analysis, respectively. Among three human breast cancer cell lines ABCG2 and COX-2 were highly expressed in MCF7-MX and MDA-MB-231 cells, respectively. The COX-2 inhibitor celecoxib up-regulated the expression of ABCG2 mRNA in MCF-7 and MCF7-MX cells, which was accompanied by increased ABCG2 protein expression. While celecoxib was able to block the 12-O-tetradecanoylphorbol-13-acetate (TPA)-mediated increase in COX-2 expression in MDA-MB-231 cells, it increased the expression of ABCG2 up to 4.27 times to the control level at mRNA level and with less intensity at protein level. Our findings provide evidence that celecoxib up-regulates ABCG2 expression in human breast cancer cells and proposed that ABCG2 is not involved in chemosensitizing effects of celecoxib
2D Gravity on with Chern-Simons Corrections
We study 2D Maxwell-dilaton gravity with higher order corrections given by
the Chern-Simons term. The model admits three distinctive vacuum
solutions. By making use of the entropy function formalism we find the entropy
of the solutions which is corrected due to the presence of the Chern-Simons
term. We observe that the form of the correction depends not only on the
coefficient of the Chern-Simons term, but also on the sign of the electric
charge; pointing toward the chiral nature of the dual CFT. Using the asymptotic
symmetry of the theory as well as requiring a consistent picture we can find
the central charge and the level of U(1) current. Upon uplifting the solutions
to three dimensions we get purely geometric solutions which will be either
or warped with an identification.Comment: 15 pages; V2: refs adde
On Effective Superpotentials and Compactification to Three Dimensions
We study four dimensional N=2 SO/SP supersymmetric gauge theory on R^3\times
S^1 deformed by a tree level superpotential. We will show that the exact
superpotential can be obtained by making use of the Lax matrix of the
corresponding integrable model which is the periodic Toda lattice. The
connection between vacua of SO(2N) and SO(2kN-2k+2) can also be seen in this
framework. Similar analysis can also be applied for SO(2N+1) and SP(2N).Comment: 18 pages, latex file, v2: typos corrected, refs adde
N=1 G_2 SYM theory and Compactification to Three Dimensions
We study four dimensional N=2 G_2 supersymmetric gauge theory on R^3\times
S^1 deformed by a tree level superpotential. We will show that the exact
superpotential can be obtained by making use of the Lax matrix of the
corresponding integrable model which is the periodic Toda lattice based on the
dual of the affine G_2 Lie algebra. At extrema of the superpotential the
Seiberg-Witten curve typically factorizes, and we study the algebraic equations
underlying this factorization. For U(N) theories the factorization was closely
related to the geometrical engineering of such gauge theories and to matrix
model descriptions, but here we will find that the geometrical interpretation
is more mysterious. Along the way we give a method to compute the gauge theory
resolvent and a suitable set of one-forms on the Seiberg-Witten curve. We will
also find evidence that the low-energy dynamics of G_2 gauge theories can
effectively be described in terms of an auxiliary hyperelliptic curve.Comment: 27 pages, late
One entropy function to rule them all
We study the entropy of extremal four dimensional black holes and five
dimensional black holes and black rings is a unified framework using Sen's
entropy function and dimensional reduction. The five dimensional black holes
and black rings we consider project down to either static or stationary black
holes in four dimensions. The analysis is done in the context of two derivative
gravity coupled to abelian gauge fields and neutral scalar fields. We apply
this formalism to various examples including minimal supergravity.Comment: 29 pages, 2 figures, revised version for publication, details adde
Coupled dark energy: Towards a general description of the dynamics
In dark energy models of scalar-field coupled to a barotropic perfect fluid,
the existence of cosmological scaling solutions restricts the Lagrangian of the
field \vp to p=X g(Xe^{\lambda \vp}), where X=-g^{\mu\nu} \partial_\mu \vp
\partial_\nu \vp /2, is a constant and is an arbitrary function.
We derive general evolution equations in an autonomous form for this Lagrangian
and investigate the stability of fixed points for several different dark energy
models--(i) ordinary (phantom) field, (ii) dilatonic ghost condensate, and
(iii) (phantom) tachyon. We find the existence of scalar-field dominant fixed
points (\Omega_\vp=1) with an accelerated expansion in all models
irrespective of the presence of the coupling between dark energy and dark
matter. These fixed points are always classically stable for a phantom field,
implying that the universe is eventually dominated by the energy density of a
scalar field if phantom is responsible for dark energy. When the equation of
state w_\vp for the field \vp is larger than -1, we find that scaling
solutions are stable if the scalar-field dominant solution is unstable, and
vice versa. Therefore in this case the final attractor is either a scaling
solution with constant \Omega_\vp satisfying 0<\Omega_\vp<1 or a
scalar-field dominant solution with \Omega_\vp=1.Comment: 21 pages, 5 figures; minor clarifications added, typos corrected and
references updated; final version to appear in JCA
Isolation and partial characterization of human amniotic epithelial cells: The effect of trypsin
Background: Despite the extensive information available in the literature, cell surface marker signature of human Amniotic Epithelial Cells (hAECs) remains controversial. The aim of the present study was to characterize immunophenotypic features, proliferative capacity and immunogenicity of hAECs. We also tested whether expression of some cell surface markers is influenced by the type of trypsin used for tissue digestion. Methods: Single cell suspensions of amniotic membranes from four human placentas were isolated by enzymatic digestion and expression of CD9, CD10, CD29, CD34, CD38, CD44, CD45, CD73, CD105, CD133, HLA-I, HLA-DR, HLA-G, SSEA-4, STRO-1 and OCT-4 was then evaluated by flow cytometry. The differential impact of four trypsin types on the yield and expression of CD105 and HLA-I was also determined. The proliferative capacity of cultured hAECs was assessed and compared in the presence and absence of Epidermal Growth Factor (EGF). To test their immunogenicity, hAECs were injected into Balb/c mice and the reactivity of hyperimmunized sera was examined by immunofluorescence staining. Results: Nearly all purified cells expressed mesenchymal markers, CD9, CD10, CD29, and CD73 and the embryonic marker, SSEA-4. A large proportion of the cells also expressed STRO-1 and OCT-4. The purified cells also expressed HLA-G and HLA-I. A very small proportion of hAECs expressed CD34, CD38, CD44, CD133 and HLA-DR. The type of trypsin used for enzymatic digestion affected both the percentage and expression of HLA-I and CD105. hAECs revealed substantial proliferative capacity only when cultured in the medium supplemented with EGF. These cells were shown to be capable of inducing high amounts of anti-donor antibodies. Conclusion: Here we provided evidence that hAECs are immunogenic cells with high level of HLA-I expression. Furthermore, this work highlighted the impact of isolation procedure on the immunophenotype of hAEC. © 2014, Avicenna Journal of Medical Biotechnology. All rights reserved